March 2016: Fusion Antibodies and MAB Discovery to collaborate on the development of fully humanized antibodies Belfast, UK and Neuried, Germany March 31st 2016: Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, a unique antibody discovery company, today announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies. Within the scope of this collaboration, Fusion Antibodies will apply its proprietary CDRxTM Multiplex platform to humanize therapeutic antibodies selected and produced by MAB Discovery. MAB Discovery will provide high-quality humanized antibodies ready for further development to potential partners. “We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization,” said Dr. Stephan Fischer, Chief Executive Officer of MAB Discovery. “The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate.” “Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery’s unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency,” said Dr. Paul Kerr, Managing Director at FusionAntibodies. About Fusion Antibodies Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies, Antibody Engineering Projects and cell line development. With 15+ years of experience in the medical research & diagnostic industry, with >50 humanized projects to date (from Rabbit, Rat, Mouse, Chicken, Llama); Fusion Antibodies have extensive experience in accelerating therapeutic immunotherapy research towards the clinic. Fusion Antibodies has the knowledge and expertise to build and deliver a modular package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRxTM technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success. Visit their website at www.fusionantibodies.com to find out more. About MAB Discovery and its technology platform MAB Discovery is focused on creating a vast repertoire of high quality monoclonal antibodies in terms of potency and epitope coverage for its clients, who include biotech and pharmaceutical companies such as Sanofi, GenMab A/S, Synthon Biopharmaceuticals and others. MAB Discovery’s proprietary technology utilizes the natural antibody maturation process following immunization. Rather than relying on conventional single hit optimization techniques of a few selected antibodies, the MAB Discovery approach creates a diverse collection of many hundreds of high affinity antibodies. The company uses state-of-the-art automation to select and clone B cells expressing matured antibodies deriving from the immunized animal’s entire repertoire to a given immunogen. Using this sophisticated high throughput approach enables MAB Discovery to select antibodies for functionality at an early stage and not just by simple binding. The MAB Discovery team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. For more information, please visit www.mabdiscovery.com. Contact: Fusion Antibodies: Dr. Paul Kerr, Managing Director +44(0) 2890 432800 paul.kerr@fusionantibodies.com MAB Discovery: Dr. Stephan Fischer, CEO +49 89 990 178-0 stephan.fischer@mabdiscovery.com For media inquiries: MC Services AG Katja Arnold +49 89 210 228-40 katja.arnold@mc-services.eu December 2015: Sanofi and MAB Discovery sign collaboration agreement for the development of antibodies against selected targets Neuried, Germany; December 14, 2015: Sanofi and MAB Discovery GmbH announced today that they have entered into a research and license agreement in the field of monoclonal antibodies. Within the scope of this collaboration, MAB Discovery will develop therapeutic antibodies for selected targets of Sanofi and thus support Sanofi in the development of antibody-based therapies. Sanofi will in return receive high-quality antibodies with the aim of identifying active substances for a number of diseases that are difficult to treat. Sanofi and MAB Discovery have agreed on a fee for the research activities. When specific milestones are achieved, the agreement provides for further performance-related payments to MAB Discovery. Financial details of the agreement were not disclosed. "Through this agreement with MAB Discovery we have found a strong collaboration in Germany to support us in bringing forward various antibody research projects with the help of its unique technology platform", said Prof. Dr. Jochen Maas, Head of Research & Development of Sanofi Germany. "This agreement is an important confirmation for the quality of our outstanding research platform. MAB Discovery is a renowned antibody specialist who focuses primarily on previously refractory diseases with strong medical needs. Our in-vivo platform based on a new high-throughput screening processes could enable the development of best-in-class antibody therapies", said Dr. Stephan Fischer, CEO of MAB Discovery. MAB Discovery uses its technology platform for the discovery of antibodies in vivo, which are based on natural immune responses in rabbits. Subsequently, the Company employs state-of-the-art technology for the cloning of antibodies directly from B-cells (a type of white blood cell). Applying new high-throughput screening processes, enables MAB Discovery to identify highly active antibodies. These identified antibodies cover a large number of different target structures (epitopes). The binding of medically active substances to endogenous targets is essential to fight diseases. The technology employed by MAB Discovery generates a large variety of antibodies. Of these antibodies, those with the highest possible biological effectiveness can then be selected and further developed. This technology has already been used successfully for targets that are difficult to address. One major advantage, among others, is that it requires neither time-consuming optimization of the target binding, nor the development of so-called surrogate antibodies. About MAB Discovery MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. MAB Discovery follows a flexible collaboration-based business model to meet the needs of their clients and has ongoing partnerships with several biotech and pharma companies. For more information please visit www.mabdiscovery.com. About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information please visit: www.sanofi.com For more information please contact: MAB Discovery: Dr. Anton Haselbeck, SVP +49 89 990 178-0 info@mabdiscovery.com For media inquiries: MC Services AG Katja Arnold Phone: +49 89 210 228-40 katja.arnold@mc-services.eu Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. May 2014: Synthon and MAB Discovery sign multi-target antibody discovery agreement Nijmegen, Netherlands and Neuried, Germany; May 6, 2014: Synthon Biopharmaceuticals BV and MAB Discovery GmbH today announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibody-drug conjugates (ADCs) and alternative antibody-based therapeutics. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state-of-the-art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which are very time-consuming and often sacrifice function. Synthon will obtain high quality antibodies in support of their strategy to create a portfolio of best-in-class antibody-based therapeutics, including ADCs. Additional details of the transaction were not disclosed. About Synthon Synthon, with headquarters in Nijmegen, The Netherlands, is an international pharmaceutical company and a leader in the field of generic medicines. The company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of next generation medicines. Synthon is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases and oncology. Synthon products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,400 staff worldwide, and in 2013 it recorded a turnover of EUR 215 million. For more information, go to www.synthon.com. About MAB Discovery MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaboration-based business model as a basis for its partnerships. Because of their unique funding situation, MAB Discovery can employ flexible business models to meet the needs of their clients. For more information, go to www.mabdiscovery.com. For more information please contact: Synthon: Fabienne Douven Director Corporate Communications +31 24 372 7700 fabienne.douven@synthon.com MAB Discovery GmbH Dr. Birgit Zech Vice President Business Development +49 89 990 178-0 info@mabdiscovery.com For media inquiries: MC Services AG Raimund Gabriel Phone: +49 89 210 228-30 raimund.gabriel@mc-services.eu March 2014: MAB Discovery GmbH signs multi-target antibody deal March 27, 2014, Neuried, Germany MAB Discovery GmbH, a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel antibody therapeutics, today announced it has entered into a collaboration with Genmab A/S (OMX: GEN) and its affiliate Genmab BV. Under the terms of the agreement, MAB Discovery will generate antibodies for multiple Genmab targets in support of their development of therapeutic antibody products. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state of the art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species-cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which is very time consuming. “We are excited to provide our rabbit-based in vivo platform to such a high quality biotech company” said Dr. Stephan Fischer, CEO of MAB Discovery, “Genmab’s antibody format technologies the DuoBody and HexaBody platforms, combined with our antibody discovery platform, could lead to the discovery of best in class therapeutic antibodies.” The deal terms are not disclosed. About MAB Discovery GmbH MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaboration-based business model as a basis for its partnerships. Because of their unique funding situation, MAB Discovery can employ flexible business models to meet the needs of their clients. For further information, please contact: MAB Discovery GmbH Dr Birgit Zech Vice President Business Development Email: birgit.zech@mabdiscovery.com Phone: +49 89 990 178-0 For media inquiries: MC Services AG Raimund Gabriel Email: raimund.gabriel@mc-services.eu Phone: +49 89 210 228-30 November 2013: MAB Discovery: a high-throughput route to superior monoclonal antibodies MAB_Discovery.pdf 112 K April 2013: MAB Discovery: Monitoring maturation. Emerging company profile in BioCentury The Bernstein Report on BioBusiness, April 8, 2013 March 2013: MAB Discovery entered into a collaboration with BioNTech of Mainz, Germany to discover monoclonal antibodies to a number of targets September 2012: MAB Discovery enters into an agreement with Top 20 Global Pharma Company Two research collaborations push MAB Discovery’s discovery platform September 27, 2012, Munich, Germany MAB Discovery, a provider of exceptional therapeutic monoclonal antibodies, announced today that they have initiated two independent research collaborations with a US oncology focused biotech and a top 20 pharmaceutical company. Employing its unique discovery platform, MAB Discovery will deliver a number of monoclonal antibodies to partner selected targets. Financial terms were not disclosed in either case. MAB Discovery employs natural immunization of wild type animals (rabbits and rats), followed by fully automated state of the art single B cell cloning and PCR methods to discover high affinity monoclonals covering extensive epitope space. Large and diverse panels of antibodies are created from B cells isolated at various times post immunization. The power of the MAB Discovery platform resides in the vast number of high quality monoclonals from which to choose candidates with desired specificity and functionality. In the case of rabbits, which have been well recognized over the years as excellent sources of high quality antibodies to virtually any antigen, the derived monoclonals are of extreme high affinity (<1nM), obviating the need for time-consuming affinity maturation campaigns with uncertain outcomes. Applications for the MAB Discovery platform range from discovery of monoclonals to novel and difficult targets (eg, GPCRs, ion channels), to finding agents suitable for ADC strategies, to making “biobetters”, etc. “I am very pleased with the speed and efficiency by which our CEO, Dr. Stephan Fischer, and his team have been able to establish and validate the platform and to launch these important collaborations”, said Dr. Lee Babiss, Chairman of MAB Discovery and CSO of PPD. “Companies such as MAB Discovery are positioned to take advantage of the increased outsourcing of discovery by large pharmas.” About MAB Discovery GmbH MAB Discovery was founded in Munich, Germany in October 2010 by a number of senior executives from Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD, MAB Discovery follows a service based business model as a basis for its collaborations. Because of this unique funding situation, MAB Discovery can employ a variety of business and collaboration structures to meet the partners’ needs. For further information, please contact: Dr. Birgit Zech Head Business Development Email: birgit.zech@mabdiscovery.com Phone: +49 89 990 178-0 July 2012: MAB Discovery entered into an agreement with an undisclosed US biotech company to develop monoclonal antibodies to a number of targets June 2012: MAB Discovery entered into an agreement with Boehringer Ingelheim for the generation of monoclonal antibodies News Events About Us Technology Partnering News Contact Careers HomeImpressumSite Map